Industry news

  1. Phase 2 study: Ibudilast's effects in progressive MS

    Phase 2 clinical trial shows that ibudilast is linked to a 48% slowing in the progression of brain atrophy compared to placebo for patients with progressive MS.

    red mri brain scan

    Read more »
  2. Vyndaqel (tafamidis): Amyloidosis treatment approved by the FDA

    Vyndaqel (tafamidis) is now approved in the U.S. after study showed increased survivorship rate and reduced hospital time due to heart related problems.

    US flag thumbs up gesture

    Read more »
  3. FDA gives go-ahead for MN166 (ibudilast) to begin phase 2b/3 clinical trials

    Approval for next phase of clinical trials puts ALS patients one step closer to accessing new treatment shown to slow disease progression.

    FDA Ibudilast molecule and pills

    Read more »
  4. Kalydeco (ivacaftor) now approved in Canada for children aged 1-2

    Based on promising results from phase III clinical trials, Health Canada has decided to extend the use of Kalydeco (ivacaftor) to include children aged 1 to 2 years. 

    toddler in park with bubles

    Read more »
  5. Children with cystic fibrosis have a chance to breathe easier

    A recent clinical trial indicates that Symkevi/Symdeko (tezacaftor/ivacaftor) can safely and effectively loosen thick, sticky mucus for children 6-11 years old.

    girl running through field

    Read more »
  6. Lung cancer medicine receives positive opinion in the EU

    CHMP's assessment supports EMA's approval of non-small cell lung cancer (NSCLC) medicine, Vizimpro (dacomitinib).

    EU approval OK hand gesture

    Read more »
  7. New cancer medicine targets tumour biomarkers anywhere in the body

    The new site-agnostic cancer medicine, Vitrakvi (larotrectinib), gets accelerated approval from the U.S. Food and Drug Administration (FDA).

    US flag thumbs up gesture

    Read more »
  8. New study supports FDA's decision to approve Copiktra (duvelisib)

    Phase III trial shows that Copiktra (duvelisib) may be an option for patients with relapsed or refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma.

    woman smiling sunny

    Read more »
  9. Cancer medicine, Lartruvo (olaratumab), does not prolong life

    After failing to show a clear benefit over chemotherapy on its own, both the FDA and EMA do not recommend Lartruvo (olaratumab) for use in combination with chemotherapy for new STS patients.

    old bench

    Read more »
  10. Onpattro (patisiran): the first RNAi therapeutic approved in the European Union

    Onpattro (patisiran) is a first-in-class treatment that slows down the progression of hereditary transthyretin amyloidosis (hATTR).

    EU approval OK hand gesture

    Read more »
Posts loader